Amyloid-beta (Aβ) fibril formation represents the final step in the amyloidogenic aggregation pathway, where soluble Aβ monomers assemble into insoluble, β-sheet-rich fibrillar structures that constitute the core of amyloid plaques in Alzheimer's disease (AD) brains. Unlike the transient oligomeric species discussed in Amyloid-beta Oligomerization Pathway, mature fibrils are stable, protease-resistant, and can persist for years in the brain[1].
The formation of Aβ fibrils is not a simple linear process but involves multiple intermediate states, conformational transitions, and strain-dependent polymorphisms that influence disease progression and therapeutic targeting. Understanding these mechanisms has become increasingly important as structural studies reveal the remarkable complexity of amyloid assemblies in the human brain[2].
Aβ fibril formation begins with primary nucleation, where monomers spontaneously assemble into a stable nucleus capable of recruiting additional monomers. This process requires overcoming a thermodynamic barrier and is the rate-limiting step in fibril formation[1:1].
The nucleus forms when Aβ monomers adopt a β-sheet-rich conformation that allows favorable intermolecular hydrogen bonding and hydrophobic interactions. Key factors influencing primary nucleation include:
Once a stable nucleus forms, elongation proceeds through the addition of monomers to the growing fibril ends. Elongation follows a nucleation-dependent polymerization model:
The elongation phase is characterized by:
All Aβ fibrils share a common cross-β architecture characterized by:
The cross-β structure provides:
Aβ fibrils exhibit remarkable structural polymorphism, with distinct strains forming in different brain regions and individuals. This strain diversity has important implications for disease heterogeneity and therapy resistance[5].
| Strain | Characteristics | Disease Association |
|---|---|---|
| Aβ40 fibrils | More flexible, 2-fold symmetry | CAA, diffuse plaques |
| Aβ42 fibrils | More rigid, 3-fold symmetry | Core plaques, rapid progression |
| PyroGlu-Aβ | N-terminally modified, highly stable | Aggressive early-onset AD |
Structural differences between strains arise from:
Secondary nucleation refers to the formation of new fibrils from existing fibril surfaces, significantly accelerating overall aggregation kinetics. This process includes:
Secondary nucleation is critical for:
As fibrils mature, they undergo structural transitions that enhance stability:
Mature fibrils exhibit:
Aβ fibrils are the major component of amyloid plaques, but plaque morphology varies:
| Plaque Type | Fibril Content | Associated Pathology |
|---|---|---|
| Core plaques | Dense Aβ42 fibrils | Severe neurodegeneration |
| Diffuse plaques | Aβ40/Aβ42 fibrils | Early stage, less correlation |
| Cerebral amyloid angiopathy | Aβ40 fibrils | Vascular dysfunction |
The role of fibrils in neurodegeneration has evolved from the original amyloid cascade hypothesis:
Understanding fibril formation has identified several therapeutic targets:
The formation of a stable Aβ nucleus represents a first-order phase transition that requires overcoming a significant free energy barrier. This barrier arises from the entropic cost of organizing disordered monomers into an ordered β-sheet-rich structure[7].
The thermodynamics of primary nucleation can be described by:
Fibril elongation follows a "dock-and-lock" mechanism where monomers rapidly associate with the fibril end (dock) followed by a conformational conversion (lock) that incorporates them into the β-sheet structure[8].
Key kinetic parameters include:
Secondary nucleation creates a positive feedback loop that dramatically accelerates amyloid formation. The rate of secondary nucleation depends on:
Metal ions play a crucial role in Aβ fibril formation through both direct binding and catalytic oxidation reactions[10].
Copper (Cu²⁺) interactions:
Iron (Fe³⁺) interactions:
Zinc (Zn²⁺):
N-terminal truncation and cyclization of glutamate produces pyroglutamate Aβ (pE3-Aβ), one of the most abundant and pathogenic Aβ species in AD brains[3:1].
Properties of pE3-Aβ:
Other disease-associated modifications include:
Laboratory studies of Aβ fibril formation employ:
| Method | What it Measures | Advantages |
|---|---|---|
| ThT fluorescence | β-sheet content | Fast, sensitive |
| AFM/EM | Fibril morphology | Direct visualization |
| smFRET | Oligomer heterogeneity | Single-molecule resolution |
| NMR | Structural dynamics | Atomic detail |
| Cryo-EM | Fibril structure | Near-atomic resolution |
Recent cryo-EM studies have revealed multiple Aβ fibril structures from AD brain tissue, demonstrating remarkable structural diversity that may correlate with clinical phenotypes[12].
The ability to seed further aggregation is a hallmark of prion-like behavior. Seeding assays measure:
Multiple classes of aggregation inhibitors have been investigated:
Metal chelators:
Natural compounds:
Designed peptides:
Antibody-based therapies target different aggregation species:
| Antibody Target | Mechanism | Clinical Status |
|---|---|---|
| Monoclonal anti-Aβ (Bapineuzumab) | Bind fibrils | Discontinued |
| Solanezumab | Bind monomers | Phase 3 |
| Aducanumab | Bind oligomers/fibrils | Approved |
| Donanemab | N-terminal targeting | Approved |
Antibodies can work through multiple mechanisms:
Emerging therapeutic strategies include:
Nanoparticle carriers:
Direct aggregation modulators:
Recent advances have revealed that Aβ fibrils exist as multiple distinct strains with different:
Understanding strain diversity is crucial for:
Modern computational approaches include:
Studies of Aβ fibrils extracted from AD brain tissue have revealed:
Aβ fibril formation represents a complex, multi-step process critical to Alzheimer's disease pathogenesis. Key concepts include:
Understanding Aβ fibril formation at the molecular level is essential for developing effective disease-modifying therapies for Alzheimer's disease.
Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012. ↩︎ ↩︎ ↩︎ ↩︎
Knowles TP, et al. The amyloid state and its assembly. Science. 2014. ↩︎
Petersen MA, et al. Pyroglutamate-modified Aβ fibrils. Nat Neurosci. 2023. ↩︎ ↩︎
Sawaya MR, et al. Atomic structures of amyloid cross-beta spines. Nature. 2009. ↩︎
Gremer L, et al. Fibril structure of Aβ40 and Aβ42. Nat Commun. 2017. ↩︎
Guo J, et al. Different amyloid-beta polymorphs. J Mol Biol. 2019. ↩︎
Walsh DM, et al. Naturally occurring oligomers of Aβ. J Biol Chem. 2005. ↩︎
Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration. Nat Rev Mol Cell Biol. 2012. ↩︎
Cohen SI, et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Nat Struct Mol Biol. 2013. ↩︎
Verma M, et al. Role of metal ions in Aβ aggregation. J Neurochem. 2015. ↩︎
House JE, et al. Copper and Aβ fibril formation. Inorg Chem. 2017. ↩︎
Ahmad S, et al. Aβ42 fibril polymorphism. Proc Natl Acad Sci USA. 2020. ↩︎
Ladiwala AR, et al. Curcumin and Aβ fibril inhibition. J Biol Chem. 2011. ↩︎
Habchi J, et al. An anticatalytic antibody against Aβ aggregation. Sci Adv. 2016. ↩︎
Sahoo BR, et al. Aβ-fibril-directed antibodies. J Immunol. 2017. ↩︎
Friedrich RP, et al. Nanoparticle-based Aβ fibril disruption. J Alzheimers Dis. 2010. ↩︎
Jiang L, et al. Substoichiometric inhibition of Aβ aggregation. Nat Commun. 2019. ↩︎
Ott S, et al. Strain-specific Aβ antibodies. Nat Neurosci. 2021. ↩︎